Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

3-D researchers patent alphav integrin inhibitors with broad indications

Sep. 29, 2000

Two-antigen combination melanoma vaccine enters phase I/II at MGH

Sep. 29, 2000

Results of marimastat/carboplatin combination trial in ovarian cancer disappointing

Sep. 29, 2000

New prostate cancer vaccine selected for clinical trials by Progenics, Cytogen

Sep. 29, 2000

Stable and safe antineoplastic agents developed at Ohio State University

Sep. 28, 2000

Series of cdk inhibitors described in Pharmacia patent

Sep. 28, 2000

Encouraging antitumor activity reported for IGT Pharma's AVLB

Sep. 28, 2000

Ilex Oncology's first angiogenesis inhibitor enters phase I in France

Sep. 28, 2000

Topical formulation of Targretin launched in U.S. for CTCL therapy

Sep. 28, 2000

Combinations with synergistic antitumor activity claimed by Pharmacia

Sep. 27, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...